J&J’s $5bn projects have much to prove
The group highlighted Carvykti, nipocalimab and milvexian among its potential mega-blockbusters.
Zynteglo gets the nod, and the hard work begins
Bluebird’s gene therapy is to be launched in the US priced $2.8m per patient, but can the company tread the cautious path to profitability?
Novo makes a rare disease push
More deals could be in the offing, but gene therapy does not appear to be a big focus.
JP Morgan 2022 roundup – Biogen in focus
Much of this week’s business development might be done and dusted, but for Biogen things are just warming up.